# A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors

> **NCT06598371** · PHASE1,PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 141 (estimated)

## Conditions studied

- Select Advanced Solid Tumors

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **DRUG:** KSQ-004EX
- **DRUG:** Interleukin-2

## Key facts

- **NCT ID:** NCT06598371
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-21
- **Primary completion:** 2039-08-01
- **Final completion:** 2041-08-01
- **Target enrollment:** 141 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06598371

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06598371, "A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06598371. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*